Multiple Sclerosis News Today10d
Ocrevus, fampridine improve walking ability in MS: Review
Fampridine, which is approved to improve walking in MS patients, and Ocrevus may help ease walking impairments, a review of ...
Pharmabiz4d
Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint
Roche announced that the phase III MUSETTE trial comparing a high dose of Ocrevus (ocrelizumab) intravenous (IV ... a =20% increase in time to perform the timed 25-foot walk (T25FW); a =20% increase ...
clinicaladvisor.com4d
High Dose Ocrelizumab Shows No Added Benefit for Relapsing MS Patients
Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing ...
PharmiWeb5d
Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OCREVUS IV 600 ...